Treatment A (Reference) for Healthy Subjects

"Our team at Power has assessed the safety of Treatment C (Test 2) to be a mere 1 out of 3 due to the limited clinical data concerning its efficacy and security."

"This clinical trial is actively enrolling 24 individuals aged 18 to 50 who can demonstrate good health. Criteria for potential participants include the following: Male or female subjects of 18 to 50 years old (inclusively), literacy in order to read, understand and sign an informed consent form, BMI between 18.5-30.0 kg/m2, normal electrocardiogram results, blood pressure and heart rate readings., compliance with study protocols and ability to complete the trial as planned by investigators; females must have undergone a surgical sterilization procedure at least 6 months prior dosing or be postmenopausal with amenorrhea for 1 year before"

"Affirmative. Published records on clinicaltrials.gov confirm that this research project, which originally went public on September 27th 2022, is actively recruiting participants. 24 individuals must be sourced from 1 medical site in order to complete the trial's requirements."

"Affirmative. Clinicaltrials.gov confirms that this clinical trial has openings for 24 participants, which was initially posted on September 27th 2022 and last updated October 6th 2022 at a single site."

"SK Life Science, Inc., the study sponsor, has outlined that Cmax is the primary objective to be measured over a span of 38 days. Additionally, they will also assess safety and tolerability through vitals signs such as systolic and diastolic blood pressure readings, pulse rate measurements, respiration rates, body temperature checks and Columbia Suicide Severity Rating Scale scores. Lastly, adverse events (AEs) are another secondary outcome being tracked for this trial."

"This experiment adheres to the inclusion criteria of 18 as a minimum age and 50 as a maximum age for participation."